nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltegravir—CCR1—Chemokine receptors bind chemokines—CCR4—malignant glioma	0.025	0.0629	CbGpPWpGaD
Raltegravir—CCR1—Peptide GPCRs—CCR4—malignant glioma	0.02	0.0504	CbGpPWpGaD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CXCR3—malignant glioma	0.0186	0.0468	CbGpPWpGaD
Raltegravir—Abnormal behaviour—Temozolomide—malignant glioma	0.0165	0.0287	CcSEcCtD
Raltegravir—Opportunistic infection—Temozolomide—malignant glioma	0.0153	0.0265	CcSEcCtD
Raltegravir—CCR1—Peptide GPCRs—CXCR3—malignant glioma	0.0149	0.0374	CbGpPWpGaD
Raltegravir—CCR1—Peptide GPCRs—BDKRB2—malignant glioma	0.0136	0.0342	CbGpPWpGaD
Raltegravir—Altered state of consciousness—Temozolomide—malignant glioma	0.0133	0.0232	CcSEcCtD
Raltegravir—UGT1A1—Irinotecan Pathway—BCHE—malignant glioma	0.0111	0.028	CbGpPWpGaD
Raltegravir—Nephropathy toxic—Carmustine—malignant glioma	0.0111	0.0193	CcSEcCtD
Raltegravir—Cerebration impaired—Temozolomide—malignant glioma	0.0104	0.0182	CcSEcCtD
Raltegravir—Cyst—Carmustine—malignant glioma	0.00951	0.0165	CcSEcCtD
Raltegravir—CCR1—Peptide ligand-binding receptors—CCR4—malignant glioma	0.00942	0.0237	CbGpPWpGaD
Raltegravir—UGT1A1—Constitutive Androstane Receptor Pathway—CYP2B6—malignant glioma	0.00942	0.0237	CbGpPWpGaD
Raltegravir—Paranoia—Carmustine—malignant glioma	0.00933	0.0162	CcSEcCtD
Raltegravir—Myopathy—Temozolomide—malignant glioma	0.00876	0.0152	CcSEcCtD
Raltegravir—Herpes zoster—Temozolomide—malignant glioma	0.00816	0.0142	CcSEcCtD
Raltegravir—CCR1—G alpha (i) signalling events—CCR4—malignant glioma	0.00795	0.02	CbGpPWpGaD
Raltegravir—Memory impairment—Temozolomide—malignant glioma	0.00783	0.0136	CcSEcCtD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—CCR4—malignant glioma	0.00738	0.0185	CbGpPWpGaD
Raltegravir—Disturbance in attention—Temozolomide—malignant glioma	0.00709	0.0123	CcSEcCtD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CXCL8—malignant glioma	0.00705	0.0177	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CXCR3—malignant glioma	0.007	0.0176	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL12A—malignant glioma	0.00685	0.0172	CbGpPWpGaD
Raltegravir—CCR1—medulla oblongata—malignant glioma	0.00667	0.244	CbGeAlD
Raltegravir—Herpes simplex—Temozolomide—malignant glioma	0.00667	0.0116	CcSEcCtD
Raltegravir—Neck pain—Carmustine—malignant glioma	0.00644	0.0112	CcSEcCtD
Raltegravir—CCR1—Peptide ligand-binding receptors—BDKRB2—malignant glioma	0.0064	0.0161	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CCR4—malignant glioma	0.00632	0.0159	CbGpPWpGaD
Raltegravir—Musculoskeletal pain—Temozolomide—malignant glioma	0.00622	0.0108	CcSEcCtD
Raltegravir—Phosphatase alkaline increased—Temozolomide—malignant glioma	0.00614	0.0107	CcSEcCtD
Raltegravir—Depressed level of consciousness—Carmustine—malignant glioma	0.00614	0.0107	CcSEcCtD
Raltegravir—CCR1—midbrain—malignant glioma	0.0061	0.223	CbGeAlD
Raltegravir—UGT1A1—Irinotecan Pathway—APC—malignant glioma	0.00605	0.0152	CbGpPWpGaD
Raltegravir—CCR1—spinal cord—malignant glioma	0.00595	0.217	CbGeAlD
Raltegravir—Depressed level of consciousness—Temozolomide—malignant glioma	0.00593	0.0103	CcSEcCtD
Raltegravir—CCR1—G alpha (i) signalling events—CXCR3—malignant glioma	0.00591	0.0148	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—KNG1—malignant glioma	0.00583	0.0146	CbGpPWpGaD
Raltegravir—Neoplasm—Carmustine—malignant glioma	0.00575	0.01	CcSEcCtD
Raltegravir—Gynaecomastia—Carmustine—malignant glioma	0.00569	0.0099	CcSEcCtD
Raltegravir—Neoplasm—Temozolomide—malignant glioma	0.00556	0.00966	CcSEcCtD
Raltegravir—Mental disability—Carmustine—malignant glioma	0.00552	0.0096	CcSEcCtD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—CXCR3—malignant glioma	0.00548	0.0138	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—BDKRB2—malignant glioma	0.0054	0.0136	CbGpPWpGaD
Raltegravir—Mental disability—Temozolomide—malignant glioma	0.00533	0.00928	CcSEcCtD
Raltegravir—Diabetes mellitus—Carmustine—malignant glioma	0.00531	0.00923	CcSEcCtD
Raltegravir—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.00513	0.00892	CcSEcCtD
Raltegravir—Gastroenteritis—Temozolomide—malignant glioma	0.00503	0.00875	CcSEcCtD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—BDKRB2—malignant glioma	0.00501	0.0126	CbGpPWpGaD
Raltegravir—Hepatic failure—Temozolomide—malignant glioma	0.00496	0.00863	CcSEcCtD
Raltegravir—CCR1—G alpha (i) signalling events—KNG1—malignant glioma	0.00491	0.0124	CbGpPWpGaD
Raltegravir—Amnesia—Carmustine—malignant glioma	0.00491	0.00855	CcSEcCtD
Raltegravir—Nasal congestion—Temozolomide—malignant glioma	0.0049	0.00852	CcSEcCtD
Raltegravir—CCR1—central nervous system—malignant glioma	0.00483	0.176	CbGeAlD
Raltegravir—CCR1—GPCR ligand binding—CCR4—malignant glioma	0.00481	0.0121	CbGpPWpGaD
Raltegravir—Hot flush—Temozolomide—malignant glioma	0.00477	0.00829	CcSEcCtD
Raltegravir—Amnesia—Temozolomide—malignant glioma	0.00475	0.00826	CcSEcCtD
Raltegravir—Menopausal symptoms—Temozolomide—malignant glioma	0.00473	0.00822	CcSEcCtD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CXCR3—malignant glioma	0.0047	0.0118	CbGpPWpGaD
Raltegravir—Face oedema—Carmustine—malignant glioma	0.00446	0.00775	CcSEcCtD
Raltegravir—Affect lability—Temozolomide—malignant glioma	0.00439	0.00764	CcSEcCtD
Raltegravir—Face oedema—Temozolomide—malignant glioma	0.00431	0.00749	CcSEcCtD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—malignant glioma	0.0043	0.0108	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—BDKRB2—malignant glioma	0.0043	0.0108	CbGpPWpGaD
Raltegravir—Mood swings—Temozolomide—malignant glioma	0.00423	0.00735	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—FTH1—malignant glioma	0.00422	0.0106	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—LATS2—malignant glioma	0.00411	0.0103	CbGpPWpGaD
Raltegravir—Dry skin—Temozolomide—malignant glioma	0.00409	0.00711	CcSEcCtD
Raltegravir—Breast disorder—Temozolomide—malignant glioma	0.00403	0.00701	CcSEcCtD
Raltegravir—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.00402	0.00699	CcSEcCtD
Raltegravir—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.00393	0.00684	CcSEcCtD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—KNG1—malignant glioma	0.00391	0.00982	CbGpPWpGaD
Raltegravir—Abdominal distension—Temozolomide—malignant glioma	0.00388	0.00675	CcSEcCtD
Raltegravir—CCR1—brain—malignant glioma	0.00383	0.14	CbGeAlD
Raltegravir—CCR1—Peptide ligand-binding receptors—F2—malignant glioma	0.00377	0.00947	CbGpPWpGaD
Raltegravir—Neutropenia—Carmustine—malignant glioma	0.00373	0.00649	CcSEcCtD
Raltegravir—Bronchitis—Temozolomide—malignant glioma	0.00371	0.00645	CcSEcCtD
Raltegravir—Neutropenia—Temozolomide—malignant glioma	0.0036	0.00627	CcSEcCtD
Raltegravir—Hyperglycaemia—Carmustine—malignant glioma	0.0036	0.00626	CcSEcCtD
Raltegravir—Upper respiratory tract infection—Temozolomide—malignant glioma	0.00358	0.00623	CcSEcCtD
Raltegravir—CCR1—GPCR ligand binding—CXCR3—malignant glioma	0.00358	0.00899	CbGpPWpGaD
Raltegravir—Erectile dysfunction—Temozolomide—malignant glioma	0.00355	0.00618	CcSEcCtD
Raltegravir—Depression—Carmustine—malignant glioma	0.00355	0.00617	CcSEcCtD
Raltegravir—Weight increased—Temozolomide—malignant glioma	0.00351	0.0061	CcSEcCtD
Raltegravir—Renal failure—Carmustine—malignant glioma	0.0035	0.00608	CcSEcCtD
Raltegravir—Weight decreased—Temozolomide—malignant glioma	0.00349	0.00607	CcSEcCtD
Raltegravir—Neuropathy peripheral—Carmustine—malignant glioma	0.00349	0.00607	CcSEcCtD
Raltegravir—Hyperglycaemia—Temozolomide—malignant glioma	0.00348	0.00605	CcSEcCtD
Raltegravir—Infestation NOS—Temozolomide—malignant glioma	0.00344	0.00598	CcSEcCtD
Raltegravir—Infestation—Temozolomide—malignant glioma	0.00344	0.00598	CcSEcCtD
Raltegravir—Depression—Temozolomide—malignant glioma	0.00343	0.00596	CcSEcCtD
Raltegravir—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.00341	0.00593	CcSEcCtD
Raltegravir—Neuropathy peripheral—Temozolomide—malignant glioma	0.00337	0.00586	CcSEcCtD
Raltegravir—CCR1—GPCR ligand binding—BDKRB2—malignant glioma	0.00327	0.00822	CbGpPWpGaD
Raltegravir—Hepatobiliary disease—Temozolomide—malignant glioma	0.00325	0.00566	CcSEcCtD
Raltegravir—Hallucination—Carmustine—malignant glioma	0.00318	0.00553	CcSEcCtD
Raltegravir—Hypoaesthesia—Carmustine—malignant glioma	0.00318	0.00553	CcSEcCtD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—HES1—malignant glioma	0.00316	0.00796	CbGpPWpGaD
Raltegravir—Oedema peripheral—Carmustine—malignant glioma	0.00315	0.00547	CcSEcCtD
Raltegravir—Connective tissue disorder—Carmustine—malignant glioma	0.00314	0.00546	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—LATS1—malignant glioma	0.00312	0.00783	CbGpPWpGaD
Raltegravir—Hepatitis—Temozolomide—malignant glioma	0.00309	0.00537	CcSEcCtD
Raltegravir—Visual impairment—Carmustine—malignant glioma	0.00308	0.00535	CcSEcCtD
Raltegravir—Hypoaesthesia—Temozolomide—malignant glioma	0.00307	0.00534	CcSEcCtD
Raltegravir—Hallucination—Temozolomide—malignant glioma	0.00307	0.00534	CcSEcCtD
Raltegravir—Urinary tract disorder—Temozolomide—malignant glioma	0.00305	0.0053	CcSEcCtD
Raltegravir—Oedema peripheral—Temozolomide—malignant glioma	0.00304	0.00529	CcSEcCtD
Raltegravir—Connective tissue disorder—Temozolomide—malignant glioma	0.00303	0.00527	CcSEcCtD
Raltegravir—Urethral disorder—Temozolomide—malignant glioma	0.00302	0.00526	CcSEcCtD
Raltegravir—Eye disorder—Carmustine—malignant glioma	0.00298	0.00519	CcSEcCtD
Raltegravir—CCR1—GPCR ligand binding—KNG1—malignant glioma	0.00298	0.00748	CbGpPWpGaD
Raltegravir—Visual impairment—Temozolomide—malignant glioma	0.00297	0.00517	CcSEcCtD
Raltegravir—UGT1A1—Phase II conjugation—GSTT1—malignant glioma	0.00294	0.00739	CbGpPWpGaD
Raltegravir—Erythema multiforme—Temozolomide—malignant glioma	0.00292	0.00508	CcSEcCtD
Raltegravir—Eye disorder—Temozolomide—malignant glioma	0.00288	0.00502	CcSEcCtD
Raltegravir—Tinnitus—Temozolomide—malignant glioma	0.00288	0.005	CcSEcCtD
Raltegravir—Cardiac disorder—Temozolomide—malignant glioma	0.00286	0.00498	CcSEcCtD
Raltegravir—Alopecia—Carmustine—malignant glioma	0.00282	0.00491	CcSEcCtD
Raltegravir—Angiopathy—Temozolomide—malignant glioma	0.0028	0.00487	CcSEcCtD
Raltegravir—Mental disorder—Carmustine—malignant glioma	0.0028	0.00487	CcSEcCtD
Raltegravir—Immune system disorder—Temozolomide—malignant glioma	0.00279	0.00485	CcSEcCtD
Raltegravir—Mediastinal disorder—Temozolomide—malignant glioma	0.00278	0.00484	CcSEcCtD
Raltegravir—Erythema—Carmustine—malignant glioma	0.00278	0.00484	CcSEcCtD
Raltegravir—Malnutrition—Carmustine—malignant glioma	0.00278	0.00484	CcSEcCtD
Raltegravir—Chills—Temozolomide—malignant glioma	0.00277	0.00482	CcSEcCtD
Raltegravir—Alopecia—Temozolomide—malignant glioma	0.00273	0.00474	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—CCR4—malignant glioma	0.00272	0.00684	CbGpPWpGaD
Raltegravir—Mental disorder—Temozolomide—malignant glioma	0.0027	0.0047	CcSEcCtD
Raltegravir—Back pain—Carmustine—malignant glioma	0.00269	0.00468	CcSEcCtD
Raltegravir—Malnutrition—Temozolomide—malignant glioma	0.00269	0.00467	CcSEcCtD
Raltegravir—Erythema—Temozolomide—malignant glioma	0.00269	0.00467	CcSEcCtD
Raltegravir—CCR1—Peptide ligand-binding receptors—CXCL8—malignant glioma	0.00265	0.00667	CbGpPWpGaD
Raltegravir—Dysgeusia—Temozolomide—malignant glioma	0.00263	0.00458	CcSEcCtD
Raltegravir—Tremor—Carmustine—malignant glioma	0.0026	0.00453	CcSEcCtD
Raltegravir—Back pain—Temozolomide—malignant glioma	0.0026	0.00452	CcSEcCtD
Raltegravir—Anaemia—Carmustine—malignant glioma	0.00257	0.00447	CcSEcCtD
Raltegravir—Agitation—Carmustine—malignant glioma	0.00255	0.00444	CcSEcCtD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—F2—malignant glioma	0.00253	0.00635	CbGpPWpGaD
Raltegravir—Tremor—Temozolomide—malignant glioma	0.00252	0.00438	CcSEcCtD
Raltegravir—Ill-defined disorder—Temozolomide—malignant glioma	0.00249	0.00434	CcSEcCtD
Raltegravir—Anaemia—Temozolomide—malignant glioma	0.00248	0.00432	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—CCR4—malignant glioma	0.00247	0.00621	CbGpPWpGaD
Raltegravir—Agitation—Temozolomide—malignant glioma	0.00247	0.00429	CcSEcCtD
Raltegravir—UGT1A1—Biological oxidations—CYP2B6—malignant glioma	0.00245	0.00617	CbGpPWpGaD
Raltegravir—Malaise—Temozolomide—malignant glioma	0.00242	0.00421	CcSEcCtD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP2B6—malignant glioma	0.00242	0.00608	CbGpPWpGaD
Raltegravir—Vertigo—Temozolomide—malignant glioma	0.00241	0.0042	CcSEcCtD
Raltegravir—Hypertension—Carmustine—malignant glioma	0.0024	0.00417	CcSEcCtD
Raltegravir—Palpitations—Temozolomide—malignant glioma	0.00237	0.00413	CcSEcCtD
Raltegravir—Myalgia—Carmustine—malignant glioma	0.00237	0.00412	CcSEcCtD
Raltegravir—Chest pain—Carmustine—malignant glioma	0.00237	0.00412	CcSEcCtD
Raltegravir—Anxiety—Carmustine—malignant glioma	0.00236	0.0041	CcSEcCtD
Raltegravir—Cough—Temozolomide—malignant glioma	0.00234	0.00408	CcSEcCtD
Raltegravir—Hypertension—Temozolomide—malignant glioma	0.00232	0.00403	CcSEcCtD
Raltegravir—Confusional state—Carmustine—malignant glioma	0.00229	0.00398	CcSEcCtD
Raltegravir—Arthralgia—Temozolomide—malignant glioma	0.00229	0.00398	CcSEcCtD
Raltegravir—Myalgia—Temozolomide—malignant glioma	0.00229	0.00398	CcSEcCtD
Raltegravir—Anxiety—Temozolomide—malignant glioma	0.00228	0.00396	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.00227	0.00395	CcSEcCtD
Raltegravir—Discomfort—Temozolomide—malignant glioma	0.00226	0.00393	CcSEcCtD
Raltegravir—Infection—Carmustine—malignant glioma	0.00225	0.00392	CcSEcCtD
Raltegravir—CCR1—G alpha (i) signalling events—CXCL8—malignant glioma	0.00224	0.00563	CbGpPWpGaD
Raltegravir—Dry mouth—Temozolomide—malignant glioma	0.00224	0.00389	CcSEcCtD
Raltegravir—Thrombocytopenia—Carmustine—malignant glioma	0.00222	0.00386	CcSEcCtD
Raltegravir—Confusional state—Temozolomide—malignant glioma	0.00221	0.00385	CcSEcCtD
Raltegravir—Infection—Temozolomide—malignant glioma	0.00218	0.00379	CcSEcCtD
Raltegravir—Nervous system disorder—Temozolomide—malignant glioma	0.00215	0.00374	CcSEcCtD
Raltegravir—Thrombocytopenia—Temozolomide—malignant glioma	0.00215	0.00373	CcSEcCtD
Raltegravir—Skin disorder—Temozolomide—malignant glioma	0.00213	0.0037	CcSEcCtD
Raltegravir—UGT1A1—Biological oxidations—CYP2C18—malignant glioma	0.00213	0.00535	CbGpPWpGaD
Raltegravir—Hyperhidrosis—Temozolomide—malignant glioma	0.00212	0.00369	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MDK—malignant glioma	0.0021	0.00529	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—CYP2C18—malignant glioma	0.0021	0.00527	CbGpPWpGaD
Raltegravir—Musculoskeletal discomfort—Carmustine—malignant glioma	0.00207	0.0036	CcSEcCtD
Raltegravir—Insomnia—Carmustine—malignant glioma	0.00205	0.00357	CcSEcCtD
Raltegravir—UGT1A1—Phase II conjugation—GSTP1—malignant glioma	0.00204	0.00512	CbGpPWpGaD
Raltegravir—Paraesthesia—Carmustine—malignant glioma	0.00204	0.00354	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—CXCR3—malignant glioma	0.00202	0.00508	CbGpPWpGaD
Raltegravir—Somnolence—Carmustine—malignant glioma	0.00202	0.00351	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—DTX1—malignant glioma	0.00201	0.00505	CbGpPWpGaD
Raltegravir—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.002	0.00347	CcSEcCtD
Raltegravir—Insomnia—Temozolomide—malignant glioma	0.00198	0.00345	CcSEcCtD
Raltegravir—Decreased appetite—Carmustine—malignant glioma	0.00197	0.00343	CcSEcCtD
Raltegravir—Paraesthesia—Temozolomide—malignant glioma	0.00197	0.00342	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Carmustine—malignant glioma	0.00196	0.00341	CcSEcCtD
Raltegravir—Somnolence—Temozolomide—malignant glioma	0.00195	0.00339	CcSEcCtD
Raltegravir—Pain—Carmustine—malignant glioma	0.00194	0.00337	CcSEcCtD
Raltegravir—Constipation—Carmustine—malignant glioma	0.00194	0.00337	CcSEcCtD
Raltegravir—Dyspepsia—Temozolomide—malignant glioma	0.00193	0.00336	CcSEcCtD
Raltegravir—CCR1—GPCR ligand binding—F2—malignant glioma	0.00192	0.00483	CbGpPWpGaD
Raltegravir—Decreased appetite—Temozolomide—malignant glioma	0.00191	0.00332	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Temozolomide—malignant glioma	0.00189	0.00329	CcSEcCtD
Raltegravir—Fatigue—Temozolomide—malignant glioma	0.00189	0.00329	CcSEcCtD
Raltegravir—Pain—Temozolomide—malignant glioma	0.00187	0.00326	CcSEcCtD
Raltegravir—Constipation—Temozolomide—malignant glioma	0.00187	0.00326	CcSEcCtD
Raltegravir—Feeling abnormal—Carmustine—malignant glioma	0.00187	0.00325	CcSEcCtD
Raltegravir—Gastrointestinal pain—Carmustine—malignant glioma	0.00185	0.00323	CcSEcCtD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—malignant glioma	0.00185	0.00465	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—BDKRB2—malignant glioma	0.00185	0.00465	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CXCR3—malignant glioma	0.00184	0.00461	CbGpPWpGaD
Raltegravir—Feeling abnormal—Temozolomide—malignant glioma	0.00181	0.00314	CcSEcCtD
Raltegravir—Body temperature increased—Carmustine—malignant glioma	0.00179	0.00312	CcSEcCtD
Raltegravir—Abdominal pain—Carmustine—malignant glioma	0.00179	0.00312	CcSEcCtD
Raltegravir—Gastrointestinal pain—Temozolomide—malignant glioma	0.00179	0.00312	CcSEcCtD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—malignant glioma	0.00178	0.00447	CbGpPWpGaD
Raltegravir—Urticaria—Temozolomide—malignant glioma	0.00174	0.00303	CcSEcCtD
Raltegravir—Body temperature increased—Temozolomide—malignant glioma	0.00173	0.00301	CcSEcCtD
Raltegravir—Abdominal pain—Temozolomide—malignant glioma	0.00173	0.00301	CcSEcCtD
Raltegravir—UGT1A1—Biological oxidations—GSTT1—malignant glioma	0.00172	0.00432	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—SLC5A5—malignant glioma	0.00169	0.00424	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—KNG1—malignant glioma	0.00168	0.00423	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—BDKRB2—malignant glioma	0.00168	0.00422	CbGpPWpGaD
Raltegravir—Hypersensitivity—Carmustine—malignant glioma	0.00167	0.00291	CcSEcCtD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—malignant glioma	0.00165	0.00415	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—malignant glioma	0.00164	0.00413	CbGpPWpGaD
Raltegravir—Asthenia—Carmustine—malignant glioma	0.00163	0.00283	CcSEcCtD
Raltegravir—Hypersensitivity—Temozolomide—malignant glioma	0.00162	0.00281	CcSEcCtD
Raltegravir—UGT1A1—Biological oxidations—PTGS1—malignant glioma	0.00161	0.00405	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—SLC6A3—malignant glioma	0.00161	0.00404	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SUFU—malignant glioma	0.00159	0.00401	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HEY2—malignant glioma	0.00158	0.00396	CbGpPWpGaD
Raltegravir—Asthenia—Temozolomide—malignant glioma	0.00157	0.00274	CcSEcCtD
Raltegravir—Diarrhoea—Carmustine—malignant glioma	0.00155	0.0027	CcSEcCtD
Raltegravir—Pruritus—Temozolomide—malignant glioma	0.00155	0.0027	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—GFAP—malignant glioma	0.00154	0.00387	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—KNG1—malignant glioma	0.00153	0.00384	CbGpPWpGaD
Raltegravir—Dizziness—Carmustine—malignant glioma	0.0015	0.00261	CcSEcCtD
Raltegravir—Diarrhoea—Temozolomide—malignant glioma	0.0015	0.00261	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—SPHK1—malignant glioma	0.00149	0.00374	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCR4—malignant glioma	0.00146	0.00367	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HEY1—malignant glioma	0.00146	0.00367	CbGpPWpGaD
Raltegravir—Dizziness—Temozolomide—malignant glioma	0.00145	0.00252	CcSEcCtD
Raltegravir—Vomiting—Carmustine—malignant glioma	0.00144	0.00251	CcSEcCtD
Raltegravir—Rash—Carmustine—malignant glioma	0.00143	0.00249	CcSEcCtD
Raltegravir—Dermatitis—Carmustine—malignant glioma	0.00143	0.00249	CcSEcCtD
Raltegravir—Headache—Carmustine—malignant glioma	0.00142	0.00247	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—HIST1H3B—malignant glioma	0.00142	0.00356	CbGpPWpGaD
Raltegravir—Vomiting—Temozolomide—malignant glioma	0.00139	0.00242	CcSEcCtD
Raltegravir—Rash—Temozolomide—malignant glioma	0.00138	0.0024	CcSEcCtD
Raltegravir—Dermatitis—Temozolomide—malignant glioma	0.00138	0.0024	CcSEcCtD
Raltegravir—Headache—Temozolomide—malignant glioma	0.00137	0.00239	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—GSTP1—malignant glioma	0.00136	0.00342	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CXCL8—malignant glioma	0.00136	0.00341	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—MMP3—malignant glioma	0.00135	0.0034	CbGpPWpGaD
Raltegravir—Nausea—Carmustine—malignant glioma	0.00135	0.00234	CcSEcCtD
Raltegravir—Nausea—Temozolomide—malignant glioma	0.0013	0.00227	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—JAG2—malignant glioma	0.00129	0.00325	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—malignant glioma	0.00126	0.00316	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—RTEL1—malignant glioma	0.00121	0.00303	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—malignant glioma	0.0012	0.00301	CbGpPWpGaD
Raltegravir—UGT1A1—Biological oxidations—GSTP1—malignant glioma	0.00119	0.003	CbGpPWpGaD
Raltegravir—UGT1A1—Metapathway biotransformation—GSTP1—malignant glioma	0.00118	0.00296	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—H3F3A—malignant glioma	0.00109	0.00275	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—F2—malignant glioma	0.00109	0.00273	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CXCR3—malignant glioma	0.00108	0.00273	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—PDGFB—malignant glioma	0.00107	0.0027	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—YWHAE—malignant glioma	0.00105	0.00265	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NTRK2—malignant glioma	0.00105	0.00265	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FLT1—malignant glioma	0.00105	0.00264	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—DUSP6—malignant glioma	0.00105	0.00263	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CG—malignant glioma	0.00104	0.00261	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—JAG1—malignant glioma	0.00103	0.00259	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NOTCH3—malignant glioma	0.00103	0.00258	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FBXW7—malignant glioma	0.00101	0.00254	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—BDKRB2—malignant glioma	0.000992	0.00249	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—F2—malignant glioma	0.000987	0.00248	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—AKT2—malignant glioma	0.000952	0.00239	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3CG—malignant glioma	0.000945	0.00237	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PTPN11—malignant glioma	0.000928	0.00233	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NOTCH2—malignant glioma	0.000922	0.00232	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CD—malignant glioma	0.000914	0.0023	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—KNG1—malignant glioma	0.000902	0.00227	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—AKT2—malignant glioma	0.000864	0.00217	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NTRK1—malignant glioma	0.00086	0.00216	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3CD—malignant glioma	0.00083	0.00209	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MMP3—malignant glioma	0.000799	0.00201	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CB—malignant glioma	0.000797	0.002	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CDKN2B—malignant glioma	0.000792	0.00199	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PTK2—malignant glioma	0.000769	0.00193	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CXCL8—malignant glioma	0.000766	0.00193	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HES1—malignant glioma	0.000756	0.0019	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NCOR1—malignant glioma	0.000751	0.00189	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—RAF1—malignant glioma	0.000741	0.00186	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—IL2—malignant glioma	0.000732	0.00184	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3CB—malignant glioma	0.000724	0.00182	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PDGFRA—malignant glioma	0.00072	0.00181	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SPP1—malignant glioma	0.000699	0.00176	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CXCL8—malignant glioma	0.000696	0.00175	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—COX8A—malignant glioma	0.000692	0.00174	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—IL2—malignant glioma	0.000665	0.00167	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TERT—malignant glioma	0.000662	0.00166	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PDGFB—malignant glioma	0.000646	0.00162	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FGFR1—malignant glioma	0.000643	0.00162	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HIF1A—malignant glioma	0.000633	0.00159	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CAV1—malignant glioma	0.000613	0.00154	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—KDR—malignant glioma	0.000606	0.00152	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ASMT—malignant glioma	0.000589	0.00148	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FN1—malignant glioma	0.000583	0.00147	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—F2—malignant glioma	0.000583	0.00147	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—BAD—malignant glioma	0.000576	0.00145	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NOTCH1—malignant glioma	0.000571	0.00143	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CD80—malignant glioma	0.000559	0.00141	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PIK3CG—malignant glioma	0.000558	0.0014	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—APC—malignant glioma	0.000558	0.0014	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—BCAN—malignant glioma	0.000553	0.00139	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—EGF—malignant glioma	0.000552	0.00139	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PTPN11—malignant glioma	0.000548	0.00138	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—BRAF—malignant glioma	0.000524	0.00132	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AKT2—malignant glioma	0.000511	0.00128	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—EGFR—malignant glioma	0.000508	0.00128	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PIK3CD—malignant glioma	0.000491	0.00123	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CA—malignant glioma	0.000486	0.00122	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—KRAS—malignant glioma	0.00048	0.00121	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—FGF2—malignant glioma	0.00047	0.00118	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—IDH2—malignant glioma	0.000446	0.00112	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3CA—malignant glioma	0.000441	0.00111	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MDM2—malignant glioma	0.000439	0.0011	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—RAF1—malignant glioma	0.000438	0.0011	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ERBB2—malignant glioma	0.000433	0.00109	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PIK3CB—malignant glioma	0.000428	0.00107	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP2B6—malignant glioma	0.000419	0.00105	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CXCL8—malignant glioma	0.000411	0.00103	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—AKT1—malignant glioma	0.000397	0.000998	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CASP3—malignant glioma	0.000393	0.000989	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IL2—malignant glioma	0.000393	0.000987	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—IDH1—malignant glioma	0.000384	0.000964	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MMP9—malignant glioma	0.000372	0.000934	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SPHK1—malignant glioma	0.000371	0.000933	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PTEN—malignant glioma	0.000369	0.000929	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CYP2C18—malignant glioma	0.000364	0.000914	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—AKT1—malignant glioma	0.00036	0.000906	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—VEGFA—malignant glioma	0.000334	0.000839	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—STAT3—malignant glioma	0.00033	0.000831	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MYC—malignant glioma	0.000307	0.000772	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—EGFR—malignant glioma	0.0003	0.000755	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTT1—malignant glioma	0.000294	0.000739	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—KRAS—malignant glioma	0.000284	0.000713	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTGS1—malignant glioma	0.000276	0.000693	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PIK3CA—malignant glioma	0.000261	0.000655	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—BCHE—malignant glioma	0.000256	0.000644	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SLC5A5—malignant glioma	0.000253	0.000636	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TP53—malignant glioma	0.000252	0.000634	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AKT1—malignant glioma	0.000213	0.000535	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GSTP1—malignant glioma	0.000204	0.000512	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CAT—malignant glioma	0.000198	0.000499	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—NCOR1—malignant glioma	0.000187	0.000471	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—CAV1—malignant glioma	0.000153	0.000384	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CG—malignant glioma	0.000139	0.00035	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PPARG—malignant glioma	0.000134	0.000337	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CD—malignant glioma	0.000122	0.000307	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CB—malignant glioma	0.000107	0.000268	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTGS2—malignant glioma	0.000106	0.000265	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTEN—malignant glioma	9.21e-05	0.000232	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CA—malignant glioma	6.5e-05	0.000163	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—AKT1—malignant glioma	5.31e-05	0.000133	CbGpPWpGaD
